Publications by authors named "Douglas B Johnson"

100Publications

Pandemic medicine: the management of advanced melanoma during COVID-19.

Melanoma Manag 2020 Jul 31;7(3):MMT45. Epub 2020 Jul 31.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2020-0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475796PMC
July 2020

MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors.

Support Care Cancer 2020 Sep 4. Epub 2020 Sep 4.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05727-zDOI Listing
September 2020

Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.

Annu Rev Pharmacol Toxicol 2020 Sep 1. Epub 2020 Sep 1.

Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP² Galilée, UNICO-GRECO Cardio-oncology Program, and Department of Pharmacology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pharmtox-022820-093805DOI Listing
September 2020

COVID-19: the Emerging Role of Medical Student Involvement.

Med Sci Educ 2020 Aug 12:1-3. Epub 2020 Aug 12.

Vanderbilt University School of Medicine, 1161 21st Ave S #D3300, Nashville, TN 37232 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40670-020-01052-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419162PMC
August 2020

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.

Lancet Oncol 2020 08;21(8):e398-e404

Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30107-8DOI Listing
August 2020

Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.

J Immunother Cancer 2020 Jul;8(2)

Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398101PMC
July 2020

Balancing Cancer Immunotherapy Efficacy and Toxicity.

J Allergy Clin Immunol Pract 2020 Jun 26. Epub 2020 Jun 26.

Renal Division, Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2020.06.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318967PMC
June 2020

Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside.

J Leukoc Biol 2020 Jun 18. Epub 2020 Jun 18.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/JLB.5BT0420-585RRDOI Listing
June 2020

Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.

Autoimmun Rev 2020 Aug 11;19(8):102586. Epub 2020 Jun 11.

Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Regional Pharmacovigilance Centre, Department of Pharmacology, Sorbonne Université, INSERM CIC Paris-Est, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102586DOI Listing
August 2020

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

Cancer 2020 Aug 28;126(15):3448-3455. Epub 2020 May 28.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32984DOI Listing
August 2020

The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.

BioDrugs 2020 Aug;34(4):495-503

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-020-00428-9DOI Listing
August 2020

COVID-19 and immune checkpoint inhibitors: initial considerations.

J Immunother Cancer 2020 05;8(1)

Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246104PMC
May 2020

Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.

Oncologist 2020 May 10. Epub 2020 May 10.

Department of Endocrinology and Reproductive Medicine, Centre de Référence des Maladies Endocriniennes Rares de la Croissance and Centre de Référence des Pathologies Gynécologiques Rares, Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418341PMC
May 2020

Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.

Cancer Immunol Res 2020 Jul 29;8(7):851-855. Epub 2020 Apr 29.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-19-0986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334081PMC
July 2020

Neurologic complications of immune checkpoint inhibitors.

Expert Opin Drug Saf 2020 Apr 11;19(4):479-488. Epub 2020 Mar 11.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2020.1738382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192781PMC
April 2020

Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.

Eur Respir J 2020 Jun 4;55(6). Epub 2020 Jun 4.

Dept of Pharmacology, INSERM CIC-1901, UNICO-GRECO Cardio-oncology Program, CLIP2 Galilée, APHP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.00038-2020DOI Listing
June 2020

Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.

Expert Rev Anticancer Ther 2020 Feb 5;20(2):137-145. Epub 2020 Feb 5.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1724539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040956PMC
February 2020

Management of V600E and V600K BRAF-Mutant Melanoma.

Curr Treat Options Oncol 2019 11 18;20(11):81. Epub 2019 Nov 18.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0680-zDOI Listing
November 2019

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.

J Immunother Cancer 2019 11 15;7(1):306. Epub 2019 Nov 15.

Vanderbilt University Medical Center, Department of Medicine, Division of Hematology and Oncology, 1301 Medical Center Drive, Nashville, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0805-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858629PMC
November 2019

Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.

Eur J Cancer 2019 12 1;123:112-115. Epub 2019 Nov 1.

Sorbonne Université, INSERM CIC-1421, AP-HP, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Department of Pharmacology, UNICO-GRECO APHP.Sorbonne Cardio-oncology program, F-75013 Paris, France; Departments of Medicine and Oncology, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.09.022DOI Listing
December 2019

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.

Cancer 2020 01 3;126(2):322-328. Epub 2019 Oct 3.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952563PMC
January 2020

Cardiovascular Toxicities Associated With Ibrutinib.

J Am Coll Cardiol 2019 10;74(13):1667-1678

Departments of Medicine and Pharmacology, Cardio-Oncology program, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.07.056DOI Listing
October 2019

Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association-In Reply.

JAMA Oncol 2019 Sep 26. Epub 2019 Sep 26.

Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.3817DOI Listing
September 2019

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

Am J Transplant 2020 03 28;20(3):879-883. Epub 2019 Oct 28.

Section of Surgical Sciences, Department of Surgery, Division of Hepatobiliary Surgery & Liver Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15617DOI Listing
March 2020

Correlates of response and outcomes with talimogene laherperpvec.

J Surg Oncol 2019 Sep 2;120(3):558-564. Epub 2019 Jul 2.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25601DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449595PMC
September 2019

Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma.

Oncologist 2019 11 18;24(11):1495-1496. Epub 2019 Jun 18.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853114PMC
November 2019

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

N Engl J Med 2019 06;380(24):2377-2379

Assistance Publique-Hôpitaux de Paris, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1901677DOI Listing
June 2019

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

J Immunother Cancer 2019 05 22;7(1):134. Epub 2019 May 22.

Department of Medicine, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0617-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530194PMC
May 2019

Immunotherapy in Older Adults with Cancer.

Curr Oncol Rep 2019 05 7;21(7):56. Epub 2019 May 7.

Division of Hematology/Oncology, Geriatrics, and Palliative Care, Institute of Cancer Outcomes and Survivorship, O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, 1600 7th Avenue South, Lowder 500, Birmingham, AL, 35233, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0806-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619507PMC
May 2019

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

J Immunother Cancer 2019 05 7;7(1):123. Epub 2019 May 7.

Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0584-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503546PMC
May 2019

Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.

Eur J Cancer 2019 05 4;113:10-13. Epub 2019 Apr 4.

Sorbonne Université, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Department of Pharmacology, F-75013 Paris, France; Departments of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.002DOI Listing
May 2019

Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.

JAMA 2019 03;321(12):1219-1220

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.22123DOI Listing
March 2019

Hematologic Complications of Immune Checkpoint Inhibitors.

Oncologist 2019 05 28;24(5):584-588. Epub 2019 Feb 28.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516131PMC
May 2019

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

J Natl Compr Canc Netw 2019 02;17(2):114-117

bDepartment of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7070DOI Listing
February 2019

Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.

Proc Natl Acad Sci U S A 2019 03 19;116(10):4583-4591. Epub 2019 Feb 19.

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1821889116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410847PMC
March 2019

Targeting tissue factor in advanced solid tumours.

Lancet Oncol 2019 03 8;20(3):318-319. Epub 2019 Feb 8.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30912-4DOI Listing
March 2019

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Cardiovasc Res 2019 04;115(5):854-868

Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvz026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452314PMC
April 2019

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Clin Cancer Res 2019 03 26;25(5):1452-1454. Epub 2018 Dec 26.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397678PMC
March 2019

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Clin Cancer Res 2019 04 21;25(8):2392-2402. Epub 2018 Nov 21.

Department of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467754PMC
April 2019

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Diabetes Care 2018 12 10;41(12):e150-e151. Epub 2018 Oct 10.

Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc18-1465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301161PMC
December 2018

Immune Checkpoint Inhibitor Toxicity in 2018.

JAMA 2018 10;320(16):1702-1703

Department of Medicine, Northwestern University Medical Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2018.13995DOI Listing
October 2018

Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.

Lancet 2018 08;392(10145):384-385

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)31556-3DOI Listing
August 2018

Class Matters: Sensitivity of -Mutant Melanoma to MAPK Inhibition.

Clin Cancer Res 2018 12 24;24(24):6107-6109. Epub 2018 Jul 24.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295213PMC
December 2018

Biomarkers for immune therapy in melanoma.

Semin Cutan Med Surg 2018 Jun;37(2):120-126

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
https://scmsjournal.com/article/abstract/biomarkers-for-immu
Publisher Site
http://dx.doi.org/10.12788/j.sder.2018.019DOI Listing
June 2018

Toxicities and outcomes: Do steroids matter?

Cancer 2018 09 5;124(18):3638-3640. Epub 2018 Jul 5.

Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214744PMC
September 2018

Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials.

JAMA Ophthalmol 2018 09;136(9):986-988

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2018.1813DOI Listing
September 2018

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.

Oncology (Williston Park) 2018 04;32(4):190-4

View Article

Download full-text PDF

Source
April 2018

Melanoma: What do all the mutations mean?

Cancer 2018 09 17;124(17):3490-3499. Epub 2018 Apr 17.

Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31345
Publisher Site
http://dx.doi.org/10.1002/cncr.31345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191351PMC
September 2018

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Lancet 2018 03;391(10124):933

Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30533-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668330PMC
March 2018

Toxicities Associated With PD-1/PD-L1 Blockade.

Cancer J 2018 Jan/Feb;24(1):36-40

From the Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00130404-201801000-0000
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784852PMC
March 2019

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.

Oncoimmunology 2017 5;6(10):e1344805. Epub 2017 Jul 5.

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1344805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665065PMC
July 2017

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

EBioMedicine 2017 Oct 19;24:43-55. Epub 2017 Sep 19.

Tennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, TN, United States; Vanderbilt University School of Medicine, Department of Cancer Biology, Nashville, TN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652019PMC
October 2017

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018